Strikingly, our finding that higher populations of Ki67+CD8+ proliferating CTLs in the treatment-naive murine TME are predictive of long-term survival under losartan+anti-PD1 therapy is directly in line with our recent clinical study where we found increased circulating Ki67+CD8+ CTLs early during durvalumab (anti-PD1) therapy in treatment-naive newly diagnosed GBM patients not on dexamethasone who had better progression-free and OS (21). The gene discussed is CD8A; the disease is glioblastoma.